The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
Stocks Steady After Strong Jobs Data Dims Rate-Cut Bets | The Close 2/11/2026
...
Read moreDetailsHome » Novo Nordisk faces a defining year in the obesity drug market. Its off to a dramatic start
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
...
Read moreDetails